左西孟旦联合托伐普坦治疗急性左心衰临床价值分析被引量：9

下载PDF

导出

摘要目的:探讨运用托伐普坦联合左西孟旦治疗急性左心衰的临床效果。方法:随机将我院2014年7月—2015年9月期间收治的92例急性左心衰患者分为两组,其中对照组采用左西孟旦治疗,而观察组在此基础上再联合托伐普坦治疗,对比两组结果。结果:治疗前,两组的24h尿量、EF、收缩压以及心率比较差异无统计学意义(P>0.05);治疗后,观察组的各项指标均优于对照组(P<0.05);观察组治疗总有效率高于对照组(P<0.05);同时,两组的不良反应发生率比较差异无统计学意义(P>0.05)。结论:临床上运用托伐普坦联合左西孟旦治疗急性左心衰效果显著。

作者晏萍

机构地区湖南省衡阳市第一人民医院心内科

出处《医学理论与实践》 2018年第16期2402-2403,共2页 The Journal of Medical Theory and Practice

关键词急性左心衰托伐普坦左西孟旦

分类号 P541.6 [天文地球—构造地质学]

引文网络
相关文献

参考文献5

1宁红红.左西孟旦注射液治疗老年慢性心力衰竭的效果观察[J].中国卫生标准管理,2016,7(1):117-118. 被引量：8
2赵大鹏,宋殿华.左西孟旦联合托伐普坦对急性心力衰竭的治疗价值分析[J].中国继续医学教育,2016,8(31):162-163. 被引量：7
3王晓琳,周元丽,孙伟,李莉.托伐普坦联合左西孟旦治疗顽固性心力衰竭的疗效观察[J].中国药房,2016,27(8):1074-1077. 被引量：43
4江芸,严瑜,李海燕.左西孟旦与托伐普坦联合治疗急性心力衰竭的临床研究[J].黑龙江医学,2017,41(8):781-782. 被引量：10
5黄俊玲,罗明.心力衰竭部分药物治疗的循证医学新进展[J].国际心血管病杂志,2011,38(1):30-33. 被引量：16

二级参考文献47

1Nisha A Gilotra,Stuart D Russell.Arginine vasopressin as a target in the treatment of acute heart failure[J].World Journal of Cardiology,2014,6(12):1252-1261. 被引量：7
2柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量：2146
3Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology[J].. Eur Heart J, 2005, 26(4) :384- 416.
4Yancy CW, Sahzberg MT, Berkowitz RL, etal. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting ( from the FUSION I trial) [J]. AmJ Cardioh 2004, 94(5) 595-601.
5Yancy CW, Singh A. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency ( from the Follow Up Serial Infusions of Nesiritide [ FUSION I] trial) [J]. Am J Cardiol,2006, 98 (2) 226-229.
6Yancy CW, Krum H, Massie BM, et al. The Second Follow up Serial Infusions of Nesiritide ( FUSION II ) trial for advanced heart failure: study rationale and design[J]. Am Heart J, 2007, 153(4) 478- 484.
7Hernandez AF, O'Connor CM, Starling RC,et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCENI> HF) [J]. Am Heart J, 2009, 157(2): 271- 277.
8Kivikko M, Lehtonen L. Levosimendan: A new inodilatory drug for the teatment of decompensated heart failure [J].Curr Pharm Des, 2005, 11(4) : 435-455.
9Braun JP, Jasulaitis D, Moshirzadeh M, et al. Levosimendan may improve survival in patients requiring meehnical assist devices for post-cardiotomy heart failure [J].Crit Care, 2006, 10(1) R17.
10Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patientswith acute decompensated heart failure: the SURVIVE Randomized Trial[J].JAMA, 2007, 297(17) : 1883- 1891.